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Objectives The objective of the study was to assess noninferiority of the polymer-free sirolimus-
eluting Yukon Choice stent (Translumina GmbH, Hechingen, Germany) compared with the polymer-
based Taxus Liberté stent (Boston Scientiﬁc, Natick, Massachusetts) with regard to the primary end-
point, in-stent late lumen loss, at 9 months in patients with diabetes mellitus.
Background The Yukon Choice stent has been evaluated in several randomized controlled trials
before, albeit to date, there has been no trial that exclusively enrolled patients with diabetes
mellitus.
Methods Patients with diabetes mellitus undergoing percutaneous coronary intervention for clini-
cally signiﬁcant de novo coronary artery stenosis were randomized 1:1 to receive either the poly-
mer-free sirolimus-eluting Yukon Choice stent or the polymer-based paclitaxel-eluting Taxus Liberté
stent.
Results A total of 240 patients were randomized. Quantitative coronary angiography was avail-
able for 79% of patients. Mean in-stent late lumen loss was 0.63  0.62 mm for the Yukon
Choice stent and 0.45  0.60 mm for the Taxus Liberté stent. Based on the pre-speciﬁed mar-
gin, the Yukon Choice stent failed to show noninferiority for the primary endpoint. During fol-
low-up, there were no signiﬁcant differences between groups regarding death, myocardial in-
farction, stent thrombosis, target lesion revascularization, target vessel revascularization, or
nontarget vessel revascularization.
Conclusions Compared with the Taxus Liberté stent, the polymer-free sirolimus-eluting Yukon Choice
stent failed to show noninferiority with regard to the primary endpoint, in-stent late lumen loss, in pa-
tients with diabetes mellitus after 9-month follow-up. Both stents showed comparable clinical efﬁcacy
and safety. (Yukon Choice Versus Taxus Liberté in Diabetes Mellitus; NCT00368953) (J Am Coll Cardiol
Intv 2011;4:452–9) © 2011 by the American College of Cardiology Foundation
From the *Department of Internal Medicine/Cardiology, University of Leipzig, Heart Center, Leipzig, Germany; †Department
of Cardiology, Zentralklinik Bad Berka, Bad Berka, Germany; and the ‡Chemnitz Heart Center, Chemnitz, Germany. The study
was supported by an unrestricted grant from Translumina GmbH (Hechingen, Germany), manufacturer of the Yukon Choice
stent. Drs. Desch and Thiele received an unrestricted grant from Translumina GmbH (Hechingen), manufacturer of the Yukon
Choice stent, for general support of the study. All other authors have reported that they have no relationships to disclose.Manuscript received September 16, 2010; revised manuscript received October 16, 2010, accepted November 16, 2010.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 4 , 2 0 1 1 Desch et al.
A P R I L 2 0 1 1 : 4 5 2 – 9 Yukon Choice Stent Versus Taxus Liberté Stent in Diabetes Mellitus
453Compared with bare-metal stents (BMS), commercially
available drug-eluting stents (DES) effectively reduce rates
of angiographic and clinical restenosis (1). Most DES
currently used in clinical practice gradually release the active
antiproliferative substance from durable polymers over the
course of several weeks to months. However, permanent
polymer coatings have been linked to delayed or incomplete
re-endothelialization, possibly caused in part by a prolonged
local inflammatory reaction (2). This might, in turn, favor
stent thrombosis, a rare but clinically often fatal complica-
tion that is more likely to occur with DES than with BMS
(3). Therefore, polymer-free DES might represent an at-
tractive alternative.
The Yukon Choice stent system (Translumina GmbH,
Hechingen, Germany) comprises a thin-strut stainless steel
stent with a polymer-free microporous surface. Sirolimus is
used as an antiproliferative agent and is deposited in the
micropores using a dedicated coating machine without the
use of a polymer.
The Yukon Choice stent has been studied in several
randomized controlled trials before (4–6). However, there
has been no trial exclusively enrolling patients with diabetes
mellitus, a subgroup of patients at an increased risk for
restenosis and stent thrombosis (2).
The LIPSIA Yukon trial is a prospective, multicenter
trial comparing the polymer-free Yukon Choice stent with
an established and widely used polymer-based stent (Taxus
Liberté, Boston Scientific, Natick, Massachusetts) in pa-
tients with diabetes mellitus undergoing percutaneous cor-
onary intervention for clinically significant de novo coronary
artery stenosis.
Methods
Patients. Three cardiac centers in Germany participated in
this prospective, randomized controlled trial (University of
Leipzig Heart Center, Zentralklinik Bad Berka, and Chem-
nitz Heart Center). Patients 18 years of age or older of
either sex were considered eligible if they had diabetes
mellitus, presented with angina pectoris or a positive stress
test, and displayed a de novo stenosis in a native coronary
artery between 50% and 99% as visually estimated on
invasive angiography amenable to percutaneous intervention
with a single stent. Patients were randomized in a 1:1 ratio
to either the polymer-free sirolimus-eluting Yukon Choice
stent or the polymer-based paclitaxel-eluting Taxus Liberté
stent. Diabetes was considered present if patients were
undergoing treatment with oral antidiabetic drugs or insulin
or had an established diagnosis of diabetes mellitus as
evidenced from medical records.
Exclusion criteria were significant unprotected left main
disease (50% stenosis by visual estimate), total occlusion
of the target vessel, in-stent restenosis, stenoses of bypass
grafts, bifurcation lesions (side branch diameter 2 mm),thrombus in target lesion, indication for coronary bypass
surgery, contraindications to contrast medium or any of the
medications used during the intervention and thereafter,
acute myocardial infarction (within 48 h after symptom
onset), severe disorders of hemostasis or platelet aggrega-
tion, pregnancy, participation in another trial, and severe
comorbidities such as malignancy.
Stent systems. The commercially available Yukon Choice
system comprises of a thin-strut (87-m) stainless steel
stent with a microporous surface. Sirolimus is used as an
antiproliferative agent and is sprayed on the stent surface
using an ethanolic 2% sirolimus coating solution and a
dedicated stent coating machine without the use of a
polymer or any other additional substances. The sterile
coating process has to be performed directly in the cathe-
terization laboratory. The concept has been applied in
several randomized controlled clinical trials before (4–6).
The stent system has received CE mark approval in the
European Union and is available in different markets in
Europe and Asia. Efficacy and safety of the Taxus Liberté
stent and its predecessor (the Taxus Express 2 stent using
a slightly different platform) have been validated exten-
sively (7,8).
Randomization and interventions.
After guidewire crossing of the
lesion, eligible patients willing to
take part in the study were ran-
domly assigned to the treatment
groups via an Internet-based
system (9) using a computer-
generated list of random numbers.
The randomization list was gen-
erated and maintained by a physician not involved in the
clinical conduct of the study. Interventionalists performing the
stent implantation procedure were aware of treatment assign-
ment. However, quantitative coronary angiography (QCA)
analysis or collection of clinical patient data were performed by
blinded personnel. Patients were not informed of treatment
assignment until completion of the study.
Lesions were required to be amenable to percutaneous
intervention with a single stent no longer than 24 mm and
a maximum diameter of 3.5 mm (the rationale being that
the Yukon Choice stent was only available at a maximum
length of 24 mm and the Taxus Liberté stent only at a
maximum diameter of 3.5 mm at the time of enrollment).
Additional stents were allowed only in cases of incomplete
lesion coverage, complications such as dissection, or other-
wise suboptimal results. In these cases, it was mandated to
use the same stent type as randomized and to change to
other stent systems only for technical failure of the ran-
domly assigned stent type or inability to cross the lesion. In
patients with 2 or more stenoses suitable for inclusion, only
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MLD  minimal luminal
diameter
QCA  quantitative coronary
angiography1 lesion was allowed to enter the study (n  3). Before
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454randomization, the interventionalist decided which lesion to
include. The choice between lesion pre-dilation or direct
stenting as well as requirement of post-dilation was left to
the discretion of the interventionalist.
All patients received intravenous unfractionated heparin
at a dose of 100 international units (IU) per kilogram body
weight or guided by activated clotting time if glycoprotein
IIb/IIIa inhibitors were given. If not pre-loaded, patients
received a loading dose of 600-mg clopidogrel immediately
before the intervention followed by 75 mg per day for 12
months. Aspirin at a dose of 100 mg per day was recom-
mended indefinitely. The choice whether to administer
glycoprotein IIb/IIIa inhibitors was left to the discretion of
the interventionalist. After percutaneous coronary interven-
tion, patients stayed in the hospital for a minimum of 24 h
before discharge. A 12-lead electrocardiogram was recorded
immediately after the procedure and creatine kinase and
creatine kinase-myocardial band subfraction were collected
after 8 and 24 h.
The protocol was approved by the local Institutional
Review Board and conducted in accordance with the prin-
ciples of the Declaration of Helsinki. All patients provided
written informed consent before enrollment.
Follow-up. In-hospital follow-up was scheduled 9 months
after the index procedure. Patients underwent a structured
interview, were examined clinically, and were asked to
undergo invasive angiography. Clinical events were verified
by hospital charts and direct contact with the treating
physician and adjudicated by a committee unaware of treat-
ment assignment.
Quantitative coronary angiography. Baseline, post-procedural,
and follow-up QCA analyses were performed in the core
laboratory at the University of Leipzig Heart Center by an
experienced single observer blinded to treatment assign-
ment. Angiograms were analyzed with a semiautomated
edge-detection software (QAngio XA Clinical Edition 7.1,
Medis Medical Imaging Systems, Leiden, the Netherlands).
Catheter tip calibration was used in all patients.
Parameters assessed were reference vessel diameter, lesion
length, minimal luminal diameter (MLD), percent diameter
stenosis, late lumen loss (the difference between MLD
immediately after the procedure and the MLD at follow-
up), in-segment binary restenosis rate (restenosis defined as
50% diameter stenosis), and pattern of restenosis. Baseline
grading of lesion complexity was performed according to a
system proposed by the American Heart Association/
American College of Cardiology (10) and patterns of
restenosis were classified according to Mehran et al. (11).
The QCA measurements were obtained for both the
stented segment (“in-stent”) and a segment covering the
stented length as well as 5-mm distal and proximal margins
(“in-segment”).
Endpoints and deﬁnitions. The primary study endpoint was
n-stent late lumen loss between groups at 9-monthollow-up angiography. Secondary angiographic endpoints
ncluded in-segment late lumen loss at 9 months, MLD and
ercent diameter stenosis after the procedure and at 9
onths, in-segment binary restenosis rate, and pattern of
estenosis.
Clinical events recorded were all-cause death, definite or
resumed cardiac death, myocardial infarction, requirement
f emergency bypass surgery at the baseline intervention,
tent thrombosis, target lesion revascularization, target ves-
el revascularization, and nontarget vessel revascularization.
urthermore, we performed a pre-specified analysis of a
ombined major cardiovascular events endpoint consisting
f definite or presumed cardiac death, myocardial infarction,
equirement of emergency bypass surgery at the baseline
ntervention, definite stent thrombosis, and target lesion
evascularization. To avoid double counting of patients with
ore than 1 event, each patient contributed only once to the
omposite major cardiovascular events endpoint.
Any death was defined as cardiac unless an unequivocal
oncardiac cause could be established (12). This included
ny death of unknown cause. Periprocedural myocardial
nfarction was defined as an elevation of creatine kinase-
yocardial band 3 the upper reference limit within the
rst 48 h after the index intervention. Thereafter, myocar-
ial infarction was defined as an increase in the creatine
inase-myocardial band levels above the reference limit.
he diagnosis of definite, probable, or possible stent throm-
osis was made according to consensus criteria published by
he Academic Research Consortium (12). Target lesion revas-
ularization was defined as any clinically indicated repeat
ercutaneous intervention of the target lesion ( treated
egment from 5 mm proximal to the stent and to 5 mm
istal to the stent) or bypass surgery of the target vessel
erformed for restenosis or other complication of the target
esion (12). Revascularization was considered clinically in-
icated if follow-up angiography showed a percent diameter
tenosis 50%, and 1 or more of the following: 1) positive
istory of angina pectoris; 2) objective signs of ischemia
n noninvasive testing; or 3) abnormal invasive fractional
ow reserve results. Target vessel revascularization was
efined as any repeat percutaneous intervention or surgical
ypass of any segment of the target vessel (including the target
esion) (12).
Statistical analysis. The objective of the study was to assess
noninferiority of the Yukon Choice stent system compared
with the Taxus Liberté stent with regard to the primary
endpoint, in-stent late lumen loss. The sample size was thus
calculated using a 1-tailed t test to show noninferiority of
the Yukon Choice stent. Based on previous studies in
diabetic patients, we expected a mean late lumen loss of 0.46
mm for the Taxus Liberté stent system and no significant
differences in mean late lumen loss between groups (13,14).
The standard deviation for late lumen loss was presumed to
be 0.40 mm. The noninferiority margin was set at 0.16 mm
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455(equaling 35% of 0.46 mm). Based on these assumptions,
100 patients per treatment group needed to be analyzed to
provide a statistical power of 0.80 at a 1-sided alpha of
0.025. Adjusting for a rate of 20% of patients not returning
for invasive angiography, 120 patients were scheduled for
randomization in each group totaling 240 patients. Sample
size was calculated using ADDPLAN (ADDPLAN GmbH,
Cologne, Germany).
For categorical variables, baseline characteristics were
compared using chi-square testing (or Fisher exact test in
cases of small cell counts). For continuous data with normal
distribution, an independent samples t test was used. Oth-
erwise, the nonparametric Wilcoxon rank-sum test was
used. Categorical variables are expressed as number and
percentage of patients. Continuous data are reported as
mean  SD. The hypothesis testing for the primary
endpoint was performed using a 1-sided noninferiority test
for which a p value 0.025 was considered statistically
significant. For all other analyses, the significance level was
set at 0.05. Statistical analyses were performed with SPSS
(version 17.0, SPSS Inc., Chicago, Illinois) and SiZ (Cytel
Inc., Cambridge, Massachusetts). Analysis of clinical data
were performed according to the intention-to-treat princi-
ple using all randomized patients regardless of the treatment
actually received. For QCA data, a slightly different ap-
proach was used: Only patients who had received at least 1
study stent in the target lesion were included in the analysis.
Results
Patient characteristics. Between September 2006 and De-
ember 2008, 240 patients were randomized and allocated
o either the polymer-free sirolimus-eluting Yukon Choice
tent or the polymer-based paclitaxel-eluting Taxus Liberté
tent. Two patients withdrew consent to use data in any
orm and another 2 patients were inadvertently randomized
wice concerning the same lesion, which was recognized
nly after completion of the study upon data analysis.
herefore, 236 patients remained for further analysis. Over-
ll, both groups had similar baseline risk profiles and
omparable lesion characteristics (Table 1).
Procedural outcome and QCA. In 1 patient in each treat-
ment arm, the study stent failed to cross the stenosis and
BMS were used instead. In 4 patients in the Yukon arm and
2 patients in the Taxus arm, the study stent was unable to
completely cover the lesion and subsequently additional
BMS were successfully implanted. Angiographic follow-up
was performed after a mean of 9.3 months with no signif-
icant differences between groups (p  0.82). Quantitative
coronary angiography was available for 95 patients (79%) in
the Yukon Choice and 92 patients (79%) in the Taxus
Liberté arms, respectively (p  1.00). Reasons for missing
QCA analyses are shown in Figure 1 and results are
summarized in Table 2. Mean in-stent late lumen loss wassignificantly lower for the Taxus Liberté than for the Yukon
Choice stent (point estimate 0.45 mm vs. 0.63 mm). Thus,
the absolute difference in mean in-stent late lumen loss
between the groups was 0.18 mm, with an upper limit of the
95% confidence interval of 0.33 mm. Based on the pre-
specified margin of 0.16 mm, the Yukon Choice stent,
Table 1. Clinical and Angiographic Characteristics at Baseline
Variable
Yukon Choice
(n  120)
Taxus Liberté
(n  116) p Value
Age, yrs 67.0 9.5 67.3 9.1 0.81
Male 83 (69) 79 (68) 0.97
Cardiovascular risk factors
Current smoking 28 (23) 31 (27) 0.65
Hypertension 118 (98) 112 (97) 0.65
Peripheral artery disease 17 (14) 11 (10) 0.36
Family history of coronary artery
disease
46 (38) 50 (43) 0.54
Body mass index, kg/m2 31.0 4.8 30.5 4.7 0.39
Left ventricular ejection fraction, % 57.6 12.6 57.3 11.0 0.87
HDL cholesterol, mmol/l 1.24 0.36 1.25 0.33 0.80
LDL cholesterol, mmol/l 2.89 0.99 3.09 1.06 0.16
Glycosylated hemoglobin, % 7.2 1.5 7.1 1.2 0.75
Glomerular ﬁltration rate,
ml/min/1.73 m2*
73.8 23.4 74.7 22.2 0.79
Prior myocardial infarction 26 (22) 26 (22) 1.0
Prior percutaneous coronary
intervention
38 (32) 33 (28) 0.69
Prior coronary artery bypass grafting 6 (5) 12 (10) 0.19
Medication
Aspirin 86 (72) 85 (73) 0.90
Statin 85 (71) 79 (68) 0.75
ACE inhibitor or ARB 105 (88) 102 (88) 1.0
Beta blocker 96 (80) 87 (75) 0.45
Diabetes mellitus
Diet only 24 (20) 17 (15) 0.36
Diet  oral antidiabetics 42 (35) 50 (43) 0.25
Insulin 54 (45) 49 (42) 0.77
Glycoprotein IIb/IIIa-inhibitor use 8 (7) 8 (7) 1.0
Lesion length, mm 13.7 4.5 13.6 6.4 0.87
Minimal luminal diameter, mm 0.6 0.3 0.6 0.3 0.73
Reference diameter, mm 2.90 0.58 2.98 0.58 0.34
Stenosis, % luminal diameter 79 9 80 9 0.45
Lesion complexity according to
AHA and ACC (10)
0.20
A 23 (19) 28 (24)
B1 58 (48) 41 (35)
B2 21 (18) 29 (25)
C 18 (15) 18 (16)
Calciﬁcation 18 (15) 27 (23) 0.16
Data are mean  SD or n (%). *Estimated according to MDRD (Modification of Diet in Renal
Disease) formula (15).
ACC American College of Cardiology; ACE angiotensin-converting enzyme; AHA Amer-
ican Heart Association; ARB angiotensin receptor blocker; HDL high-density lipoprotein;
LDL low-density lipoprotein.therefore, failed to show noninferiority for the primary
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456endpoint, in-stent late lumen loss. In the study protocol, we
did not specifically pre-specify testing for superiority once
noninferiority is rejected. However, had such an analysis
been planned, 2-tailed results would show superiority for
the Taxus Liberté stent over the polymer-free sirolimus-
eluting Yukon Choice stent system with regard to the
primary endpoint (p  0.04). At follow-up, 17 (18%)
ngiographic target lesion restenoses were found in the
ukon Choice arm and 14 (15%) in the Taxus Liberté arm
p  0.77). Of these, 12 (11%) and 14 (13%) required
linically indicated percutaneous reintervention or bypass
urgery (p  0.66). Morphological appearances of resteno-
ses are presented in Table 2.
Clinical events. Clinical follow-up was available for 232
98%) of patients after a mean of 8.9 months with no
Figure 1. Study Flow Chart
Flow chart showing number of patients enrolled and patients receiving clinicaignificant differences between groups (p  0.34) (Fig. 1).uring follow-up, there were no significant differences
etween stent groups regarding all-cause death, definite or
resumed cardiac death, myocardial infarction, requirement
f emergency bypass surgery at the baseline intervention,
tent thrombosis, target lesion revascularization, target ves-
el revascularization, or nontarget vessel revascularization
Table 3). The pre-specified combined major cardiovascular
vents endpoint also showed no differences (Yukon Choice:
7 events; Taxus Liberté: 17 events; p  1.0).
iscussion
The major results of this prospective, randomized controlled
multicenter trial can be summarized as follows: compared
with the paclitaxel-eluting polymer-based Taxus Liberté
angiographic follow-up. QCA  quantitative coronary angiography.stent, the sirolimus-eluting polymer-free Yukon Choice
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457stent system failed to show noninferiority for the primary
endpoint, in-stent late lumen loss. There were no significant
differences in clinical outcome.
The late lumen loss point estimate of 0.45 mm for the
Taxus Liberté stent measured in the present study is well in
line with previous trials examining paclitaxel-eluting stents
in diabetic patients (13,14,16,17). Late lumen loss data for
the Yukon Choice stent system in patients with diabetes
mellitus have so far not been published. The exact reasons
for the higher late lumen loss in the Yukon Choice arm
remain unclear. In a previous trial of diabetic patients with
angiographic follow-up after 6 months, a polymer-based
sirolimus-eluting stent (Cypher, Cordis, Johnson & John-
son, Bridgewater, New Jersey) showed significantly lower
in-stent late lumen loss than a paclitaxel-eluting stent
(Taxus Express 2) did (0.19 0.44 mm vs. 0.46 0.64 mm,
p  0.001) (13). Therefore, it seems unlikely that sirolimus
tself played a dominant role for the observed differences.
he polymer-free coating strategy of the Yukon Choice
Table 2. Results of Quantitative Coronary Angiography
Variable
Yukon Choice
(n  95)
Taxus Liberté
(n  92)
p
Value
Stent length, mm 16.2 4.3 17.3 4.9 0.13
Stent diameter, mm 3.0 0.3 2.9 0.3 0.52
Pre-dilation 33 (35) 25 (27) 0.34
Post-dilation 6 (5) 6 (5) 1.0
1 stent implanted 18 (19) 14 (15) 0.63
Minimal luminal diameter, in-stent, mm
After PCI 2.4 0.5 2.5 0.5 0.17
At follow-up 1.8 0.8 2.1 0.7 0.01
Minimal luminal diameter, in-segment, mm
After PCI 2.2 0.6 2.2 0.5 0.27
At follow-up 1.7 0.7 1.9 0.7 0.02
Stenosis, in-stent, % luminal diameter
After PCI 20 9 19 8 0.19
At follow-up 39 22 33 20 0.06
Stenosis, in-segment, % luminal diameter
After PCI 29 11 28 11 0.62
At follow-up 42 21 37 19 0.08
Late lumen loss, in-stent, mm 0.63 0.62 0.45 0.60 0.04
Late lumen loss, in-segment, mm 0.44 0.65 0.29 0.59 0.11
In-segment binary angiographic restenosis 17 (18) 14 (15) 0.77
Pattern of restenosis 0.66
IA — —
IB 4 (23) 7 (50)
IC 6 (35) 4 (29)
ID 1 (6) —
II 2 (12) 1 (7)
III 3 (18) 1 (7)
IV 1 (6) 1 (7)
Data are mean SD or n (%).
PCI percutaneous coronary intervention.tent system might have resulted in altered drug releaseinetics and uptake into the vessel wall. It has also been
peculated that the total amount of drug coated onto the
truts of the Yukon Choice stent might be too low resulting
n suboptimal antiproliferative efficacy (18). However, a
ose-finding study for the polymer-free Yukon stent found
hat a 2% sirolimus coating solution has a strong antirest-
notic efficacy with a late loss of 0.46 mm after 9 months
ngiographic follow-up (4).
Another important aspect relates to a postulated late
catch-up” phenomenon of polymer-based DES. In a pre-
ious study comparing the Cypher, Taxus Express 2, and
rst-generation Yukon stent (predecessor of the Yukon
hoice stent with a slightly different stent platform), an-
iographic follow-up was performed between 6 and 8
onths and again 2 years after stent implantation (19).
hereas both the Cypher and Taxus Express 2 stent
ontinued to show ongoing increases in late lumen loss
etween the 2 time points, this was not the case for the
ukon stent. It was hypothesized that the permanent
olymer coating of the Cypher and Taxus Express 2 stents
ight lead to a persisting inflammatory response resulting
n delayed healing and continued neointimal formation. In
he present study, angiographic follow-up at 9 months
ight, therefore, have been suboptimal to detect the true
nal differences in late lumen loss between the 2 stents.
Previous trials of the Yukon/Yukon Choice stent system. The
first-generation Yukon stent has been used in several ran-
domized controlled trials before, albeit to date, there has
been no trial exclusively enrolling patients with diabetes
mellitus (4–6). A comparison between the Yukon stent and
a paclitaxel-eluting stent (Taxus Express 2) in 450 patients
with coronary heart disease reported a mean in-stent late
lumen loss of 0.48 mm for both groups—a result demon-
strating noninferiority of the Yukon stent (6). Only a subset
Table 3. Clinical Outcome
Variable
Yukon Choice
(n  118)
Taxus Liberté
(n  114)
p
Value
All-cause death 6 (5) 3 (3) 0.5
Deﬁnite or presumed cardiac death 4 (3) 3 (3) 1.0
Myocardial infarction 4 (3) 1 (1) 0.37
Procedure-related — 1 (1)
Nonprocedure-related 4 (3) —
Conversion to emergency bypass surgery
at index intervention
— 1 (1) 0.49
Stent thrombosis
Deﬁnite — —
Probable — —
Possible 4 (3) 3 (3) 1.0
Target lesion revascularization 12 (11) 14 (13) 0.66
Target vessel revascularization 25 (22) 29 (26) 0.51
Nontarget vessel revascularization 13 (12) 17 (15) 0.42Data are n (%).
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458of patients (29%) had diabetes mellitus, which might, in
part, explain the significantly lower late lumen loss value in
the Yukon arm compared with the present trial.
In another trial, the first-generation Yukon stent failed to
show noninferiority compared with the Cypher stent with
regard to in-stent late lumen loss in a mixed population of
patients with coronary heart disease at 9 months angiographic
follow-up, enrolling approximately one-quarter of patients
with diabetes mellitus (mean late lumen loss: 0.47 0.56 mm
vs. 0.23  0.46 mm, p  0.94 for noninferiority) (5).
owever, 2-year follow-up data of the same patient cohort
ave recently been published, again showing a late catch-up
henomenon for the Cypher stent, but no catch-up for the
olymer-free Yukon stent (20).
A nonrandomized single center registry comparing the
ukon Choice and the Taxus Liberté stent in 410 patients
ith symptomatic coronary artery disease covering a wide
linical spectrum (including, e.g., acute coronary syndrome)
eported a higher rate of target lesion revascularization at 9
nd 12 months to the disadvantage of the Yukon Choice
tent (18). However, the investigators also pointed to the
act that, because of superior flexibility and trackability, the
ukon Choice stent might have been used preferentially in
ore complex lesions than the Taxus Liberté stent was (18).
The differences in the late catch-up behavior of the
olymer-free Yukon stent might be further explained by
nother randomized controlled clinical trial comparing the
ypher stent with the Yukon stent using optical coherence
omography. The study showed better stent strut coverage
97.2% vs. 88.3% after 3 months, p  0.03) and a signifi-
antly lower number of protruding struts for the Yukon
tent (4.8 vs. 26.5, p  0.001), indicating a superior healing
process (21).
Margin of noninferiority. The choice of the noninferiority
argin is of great importance. Selecting an appropriate
argin can be based on both statistical and clinical grounds
22). Statistical reasoning is based on obtaining an estimate
f the therapeutic effect of the active control (paclitaxel-
luting stent) over “placebo” (BMS for the present situation)
rom historical data. The choice of margin is then set at a
raction of the active control effect to ensure with high
robability that (as a minimal requirement) the new treat-
ent (Yukon Choice stent) is at least more efficacious than
are-metal stenting. With the approach based on clinical
udgment, the margin is set on the maximum clinically accept-
ble difference that one is willing to give up in return for the
otential secondary benefits of the new therapy. For the
resent study, the decision to adopt a margin of noninferiority
f 0.16 mm was based on a previous trial in diabetic patients
hat reported a mean in-stent late lumen loss of 0.46 mm for
paclitaxel-eluting stent (13). The margin corresponds to
ne-third of this observed late lumen loss.
Study limitations. The primary endpoint, in-stent late lu-
men loss, as a measure of neointimal hyperplasia is asurrogate endpoint and not a truly patient-relevant end-
point. Although its predictive strength for the clinical
endpoint target lesion revascularization has been validated
(23), the limitations of surrogate endpoint should be kept in
mind (24).
The limited sample size might have prevented the detec-
tion of differences in clinical outcome reflecting the possibility
of type II error (the error of failing to observe a difference when
in truth there is one).
The selection of an appropriate control stent is of major
importance in comparative studies of DES. We used the
paclitaxel-eluting Taxus Liberté stent as a comparator.
Recent meta-analytic data of randomized controlled trials in
patients with diabetes mellitus indicate that the Cypher
stent might be superior to polymer-based paclitaxel-eluting
stents with regard to target lesion revascularization albeit
without differences in death, stent thrombosis, and myocar-
dial infarction (25). However, this was unclear at the time of
planning the trial design.
Sample size calculation was based on 100 patients in each
arm to provide a statistical power of 0.80. However, as
explained earlier, QCA was available in only 95 patients
(Yukon Choice) and 92 patients (Taxus Liberté), respec-
tively. However, given the final results it is highly unlikely
that QCA of 100 patients per arm would have resulted in
demonstration of noninferiority for the Yukon Choice stent.
Finally, we enrolled only patients with diabetes mellitus
and clinically stable coronary heart disease and used rela-
tively stringent angiographic inclusion criteria excluding, for
example, chronic total occlusions, bifurcation lesions, in-
stent restenoses, or bypass graft stenoses. Therefore, the
results obtained in the present study should not be uncrit-
ically extrapolated to different patients or lesion types.
Conclusions
In this randomized head-to-head comparison in patients with
diabetes mellitus, the polymer-free sirolimus-eluting Yukon
Choice stent system failed to demonstrate noninferiority com-
pared with the Taxus Liberté stent with regard to the primary
endpoint, in-stent late lumen loss, at 9-month angiographic
follow-up. There were no significant differences in angio-
graphic binary restenosis rate or clinical events such as target
lesion revascularization. For a final conclusion regarding the
clinical outcome of the 2 different stent coating concepts, it is
essential to obtain long-term follow-up data to evaluate the
influence of late catch-up and to further study rare safety
endpoints such as very late stent thrombosis.
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